Q-omics provides the consensus-scored PCED1B profile across patient tissues and cancer cell-line models. PCED1B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PCED1B is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, PCED1B RNA expression shows 19,535 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, HNSC, and GBM as cancer lineages where PCED1B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCED1B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCED1B survival associations across molecular data types. PCED1B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCED1B RNA expression–survival associations across cancer types. High PCED1B expression shows unfavorable associations in UVM, LGG and KIRP, but favorable associations in SKCM, BLCA and ACC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PCED1B RNA expression.
This table summarizes PCED1B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PCED1B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCED1B shows lower tumor expression in UCEC and LUSC and higher tumor expression in HNSC, THCA, KIRC and STAD. The HNSC box plot shows higher PCED1B RNA expression in tumor versus normal tissue (log2 FC = +1.480, t-test p < 0.001).
This table shows molecular features associated with PCED1B in patient tissues and cancer cell lines. In patient samples, PCED1B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PCED1B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
